|
|
(Transportation-News.com, August 23, 2012 ) New York, NY -- For months investors had speculated upon a key catalyst for Implant Sciences (IMSC) that could potentially launch the company into the mainstream of homeland defense and global security, but a notable update from the company on Tuesday helped turn that speculation into a swift dose of reality. It had been previously known that the Implant Sciences Quantum Sniffer (QS) B220 benchtop explosive trace detection (ETD) device was being tested by the Transportation Security Laboratory (TSL), the testing body of the Transportation Security Administration (TSA), as part of an ongoing process to gain "approval" by the TSA for use in the arena of homeland defense in the United States.
VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, continues to follow this key development and believes that developments over the next month could have significant implications on Implant's growth potential and share price.
Full report available: http://vfcsstockhouse.com/blog/article/-implant-sciences-key-catalyst-confirmed
Earlier this week I incorrectly noted that the date of August 27th had been "long advertised" by the company as the expected decision date by the TSA, but the truth is actually that the late summer time frame is the more accurate representation of this statement and the exact date of 27 August was merely speculation on the part of various sources on the Internet, based mainly on filings and routine TSA standard operating procedures.
Implant, however, provided an accurate representation of current expectations via a Tuesday afternoon press release that stated the company received notice last week that the QS-B220 Explosives and Narcotics Trace Detector had "successfully completed the certification readiness testing" with the TSL and that the device was heading into the final stages of approval by "undergoing the final independent validation testing for TSA qualification for air cargo screening."
That last statement in itself could be very telling as the one date that is a certainty is the December 3rd mandate by the TSA that all inbound-US air cargo on passenger airliners will be screened for explosive traces. Given that President and CEO, Glenn D. Bolduc, noted in the Tuesday release that "we remain confident in our system's performance and are hopeful that we will have good news to report to our shareholders by the end of our fiscal first quarter (ended September 30, 2012)," the B220 could receive the necessary approvals in plenty of time to help the TSA achieve its December mandate. Because the device is being streamlined and tested in the final phases specifically for air cargo, indications are that the company has specifically communicated its intentions to the TSA to apply for contracts and/or lobby for sales specifically related to this cargo screening mandate.
The next few week, as also noted by CEO Bolduc, will be a quiet period for the company as the approval and validation process concludes, but it is crunch time now for the company and its investors as a potential TSA approval would have similar implications for Implant Sciences as an FDA approval for a small biotech or pharmaceutical company. Knowing the size and scope of similar government security contracts, which recently have been valued at as much as half a billion dollars, and predicting the drastic growth in airport and airline security over the next few years, it is fairly easy to speculate that IMSC's current market cap could multiply significantly, should this approval come through.
Investing solely on catalysts could sometimes prove risky, as shares in companies not receiving expected approval often rapidly decline, but the news that the device has made it to the final phases of approval are a worthy validation of its success thus far and increase the possibilities, in my opinion, that a full approval could take place. Investors may be starting to take notice, too, as IMSC shares quickly rebounded on Wednesday following a Tuesday slide before the news hit the wires.
This is an abbreviated report. Visit http://vfcsstockhouse.com for complete version.
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
